Study: GSK cervical cancer vaccine promising for older women

06/5/2006 | MSNBC

GlaxoSmithKline reports its cervical cancer vaccine Cervarix, a likely competitor to Merck's Gardasil, produced immune responses in all women ages 15 to 55 in a clinical study. The company said the study was the first evidence such a vaccine may be effective in women ages 26 and older and also reported the vaccine was "generally safe and well-tolerated."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA